Appajosyula Sireesh

Insider purchases 1.25M shares of HEPA at distressed valuation amid severe stock decline and ongoing losses

An insider has purchased over a million shares of Hepion Pharmaceuticals at a depressed price, signaling belief in a potential turnaround despite the company's dire financial condition. The stock has collapsed significantly from its recent highs and is trading near multi-year lows, suggesting either capitulation selling or a contrarian accumulation opportunity. Fundamentally, Hepion is unprofitable with zero revenue and substantial quarterly losses, indicating the company is in a pre-commercial or failed development stage burning through cash. This insider buy at rock-bottom levels could represent either conviction in hidden value or an attempt to prop up a struggling asset—the distinction matters significantly for investors. Without visibility into the insider's historical track record or upcoming catalysts (clinical trials, partnerships, etc.), this trade warrants close monitoring to determine whether this represents savvy bottom-fishing or a warning sign of desperation.

CEO Appajosyula Sireesh bought 61,496 shares ($90,972.68) at $1.48 in 2 separate purchases; stock now trades at $1.31, down 69.0% from 52-week high of $4.22.

Appajosyula Sireesh, CEO of Tharimmune, Inc., executed two purchases totaling 61,496 shares for $90,972.68, increasing his holdings from 3.4K to 64.9K shares—a +1823.7% increase. The transaction occurs against a backdrop of significant deterioration in stock price: shares are currently $1.31, down 69.0% from the 52-week high of $4.22. His prior buy at THAR on 2024-11-13 resulted in a 90-day return of -5.4%, and the company reported a net income of -$2,541,704.00 over its most recent full fiscal year, indicating material unprofitability. A cluster pattern is present: 2 other insiders also bought within the past 14 days. The magnitude of the CEO's position accumulation combined with the concurrent insider buying activity and substantial stock price decline warrants examination of what fundamental or strategic information may underlie this concentrated buying at depressed valuations.

COO Sireesh bought 5,000 THAR shares at $2.02; holdings doubled to 10.8K. Stock down 97.2% from $78.75 high; co. posted -$3.8M net income.

Appajosyula Sireesh, Chief Operating Officer, purchased 5,000 shares at $2.02 on 2024-11-13, doubling his open-market position from 5,758 to 10,758 shares. The purchase follows a prior buy at the same ticker on 2024-10-08 (which showed a +25.9% 30-day return). The company is trading at $2.18, down 97.2% from its 52-week high of $78.75, reflecting a dramatic valuation collapse. Concurrent with this severe price decline, Tharimmune reported a full fiscal year net loss of -$3,795,852 ($-3.8M) on a market cap of only $3,239,560.66 ($3.2M), indicating the company is deeply unprofitable relative to its market value. The timing of this insider accumulation during an extreme drawdown warrants monitoring of both company fundamentals and market conditions to determine whether the execution reflects informed judgment or exposure to deteriorating operations.

COO Sireesh buys 5,000 THAR shares at $1.93 as stock plunges 97.9% from $97.50 high

Appajosyula Sireesh, Chief Operating Officer of Tharimmune, purchased 5,000 shares at $1.93, increasing his holdings by 44.0% to 16,364 shares. The purchase occurs against a backdrop of severe stock deterioration: the current price of $2.03 sits 97.9% below the 52-week high of $97.50, with the stock down 32.3% over 30 days and 44.5% over 90 days. The company remains unprofitable with a full-year net income of -$2,325,057.00 and a market cap of only $2,331,982.80. An insider acquisition at depressed valuations from a company's leadership warrants scrutiny given the company's negative earnings trajectory and the magnitude of the stock's prior collapse.